Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 -0.0502607620546252 -0.0577722827919524
Stock impact report

Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals [Seeking Alpha]

Beyond Air, Inc. (XAIR) 
Company Research Source: Seeking Alpha
The companies had entered into a letter of intent in January 2026. The letter of intent expired on March 9, 2026, in accordance with its terms, and the parties did not enter into a definitive agreement. XAIR premarket to $0.8968. Source: Press Release More on Beyond Air Beyond Air Q3 2026 Earnings Preview Beyond Air appoints Dan Moorhead as CFO Seeking Alpha's Quant Rating on Beyond Air Historical earnings data for Beyond Air Show less Read more
Impact Snapshot
Event Time:
XAIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for XAIR alerts
Opt-in for
XAIR alerts

from News Quantified
Opt-in for
XAIR alerts

from News Quantified